Trends in Anterior Lumbar Interbody Fusion in the United States: A MarketScan Study From 2007 to 2014

Clin Spine Surg. 2020 Jun;33(5):E226-E230. doi: 10.1097/BSD.0000000000000904.

Abstract

Background: Although the incidence of spinal fusions has increased significantly in the United States over the last quarter century, national trends of anterior lumbar interbody fusion (ALIF) utilization are not known.

Purpose: The objective of this study was to characterize trends, clinical characteristics, risk factors associated with, and outcomes of ALIF in the United States.

Study design: This was an epidemiological study using national administrative data from the MarketScan database.

Methods: Using a large administrative database, we identified adults who underwent ALIF in the United States from 2007 to 2014. The incidence of ALIF was studied longitudinally over time and across geographic regions in the United States. Data related to postoperative complications, length of stay, readmission, and cost were collected.

Results: We identified 49,945 patients that underwent ALIF in the United States between 2007 and 2014. The total number of ALIF procedures increased from 3650 in 2007 to 6151 in 2014, accounting for an average increase of 24.07% annually. The Southern United States performed the highest number of ALIFs. The most common conditions treated were degenerative disc disease and spondylolisthesis. Over one third of patients (34.6%) underwent multilevel fusion. The most common complications were iron deficiency anemia, urinary tract infections, and pulmonary complications. Hospital and physician pay increased significantly during the study period.

Conclusions: For the first time in our knowledge, we identified national trends in ALIF utilization, outcomes, and cost using a large administrative database. Our study reaffirms prior work that has demonstrated low rates of complications, mortality, and readmission following ALIF.

Level of evidence: Level III.

MeSH terms

  • Adult
  • Aged
  • Bone Morphogenetic Protein 2 / therapeutic use
  • Data Collection
  • Databases, Factual
  • Humans
  • Length of Stay
  • Longitudinal Studies
  • Lumbar Vertebrae / surgery*
  • Lumbosacral Region / surgery
  • Middle Aged
  • Orthopedics / trends*
  • Patient Readmission
  • Postoperative Complications / etiology
  • Recombinant Proteins / therapeutic use
  • Retrospective Studies
  • Risk Factors
  • Spinal Fusion / instrumentation*
  • Spinal Fusion / methods*
  • Spondylolisthesis / surgery
  • Transforming Growth Factor beta / therapeutic use
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Bone Morphogenetic Protein 2
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2